Sandoz reshapes biosimilar and generics leadership to seize upcoming patent cliff

The latest update is out from Sandoz Group Ltd ( (CH:SDZ) ).

Sandoz is restructuring to sharpen its focus on biosimilars and generics as it targets a projected “golden decade” of loss-of-exclusivity opportunities worth more than USD 650 billion. The company has created a dedicated global biosimilar development, manufacturing and supply unit, appointing industry veteran Armin Metzger as President of this new division and member of the Executive Committee, while redefining leadership roles in its core generics business.

By consolidating biosimilar activities under a single executive and giving generics its own specialized development and manufacturing heads, Sandoz aims to speed decision-making, deepen vertical integration and tailor strategies to distinct market dynamics in each segment. The move reinforces its positioning as the only pure-play leader across both biosimilars and generics, is intended to strengthen its competitive edge in high-volume generics, and leaves the company’s 2026 financial guidance and medium-term outlook unchanged.

In parallel, Sandoz is streamlining its regional governance by having the German business report into the President Europe, aligning Germany’s representation at the executive committee level with a broader European lens. These organizational changes are designed to unlock biosimilar growth potential, support sustainable expansion, and better capture upcoming market opportunities without altering current financial targets.

The most recent analyst rating on (CH:SDZ) stock is a Buy with a CHF80.00 price target. To see the full list of analyst forecasts on Sandoz Group Ltd stock, see the CH:SDZ Stock Forecast page.

More about Sandoz Group Ltd

Sandoz Group AG is a Basel-based global leader in affordable medicines, specializing in generics and biosimilars that span treatments from common conditions to cancer. With a portfolio of about 1,300 products, operations in more than 100 nationalities, and 2025 net sales of USD 11.1 billion, the company focuses on expanding patient access and generating significant healthcare savings worldwide.

Tracing its heritage back to 1886, Sandoz celebrates major milestones in 2026, including 20 years in biosimilars and 80 years in antibiotics manufacturing. Generics account for roughly 70% of its global net sales and an even larger share by volume, underlining its positioning as a pure-play provider of high-volume, lower-cost medicines with strong leadership across both generics and biosimilars.

Average Trading Volume: 789,364

Technical Sentiment Signal: Buy

Current Market Cap: CHF28.13B

See more data about SDZ stock on TipRanks’ Stock Analysis page.